Last year, we created The “WHY” Project at Biosero. The idea started with a discussion about “WHY.” WHY do we do our work? WHY do we work at Biosero? Biosero team members shared their “WHY” statements with each other and it became clear that their work at Biosero has more profound meaning to them personally than just earning a paycheck.
As employees shared their WHY statements, there was a commonality. They are proud to be part of a company that accelerates research that delivers cures. We take pride knowing that our customers have launched pharmaceuticals that cure Hepatitis C, reduce pain without addictive side effects or save the lives of cancer patients – this is our WHY and what drives us at Biosero. The team at Biosero knows our efforts impact the speed of drug discovery. We make a difference!
From that conversation, Biosero decided that every year the employees at Biosero will nominate and vote for a philanthropic cause to receive a contribution from Biosero. This year our team members have chosen to contribute $5,000 to the Cancer Research Institute. Cancer has impacted almost everyone at Biosero. We would love to see the day when there is a cure.
This week our team proudly presented the donation check to Jill O’Donnell-Tormey, Ph.D., CEO and Director of Scientific Affairs for the Cancer Research Institute (CRI).
The Cancer Research Institute (CRI), established in 1953, is the world’s leading nonprofit organization dedicated exclusively to transforming cancer patient care by advancing scientific efforts to develop new and effective immune system-based strategies to prevent, diagnose, treat, and eventually cure all cancers. CRI is guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and 26 members of the National Academy of Sciences. CRI has invested $384 million in support of research conducted by immunologists and tumor immunologists at the world’s leading medical centers and universities. They have contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go to cancerresearch.org.
Written By: Tom Gilman